Journal of Diabetes and Its Complications
Volume 20, Issue 3 , Pages 179-183 , May 2006

Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: A randomized crossover study

  • Michio Shimabukuro

      Affiliations

    • Corresponding Author InformationCorresponding author. Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. Tel.: +81 98 895 1146; fax: +81 98 895 1415.
    • ,
  • Namio Higa
    • ,
  • Nobuyuki Takasu

Received 29 December 2004 ,Revised 23 June 2005 ,Accepted 24 June 2005.

References 

  1. Antoniades C, Tousoulis D, Tauntas C, Tentolouris C, Toutouza M, Vasiliadou C, et al. Vascular endothelium and inflammatory process, in patients with combined type 2 diabetes mellitus and coronary atherosclerosis: The effect of vitamin C. Diabetic Medicine. 2004;21:552–558
  2. Ashcroft FM, Gribble FM. Tissue specific effects of sulphonylureas: Lessons from studies of cloned KATP channels. Journal of Diabetes and its Complications. 2000;14:192–196
  3. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction. Endocrine Reviews. 2001;2:36–52
  4. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus; effect of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229
  5. Dhindsa P, Davis KR, Donnelly R. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with type 2 diabetes: A double-blind, crossover study. British Journal of Clinical Pharmacology. 2003;55:616–619
  6. Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabetic Medicine. 2002;19:752–757
  7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18:499–502
  8. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulphonylureas: Studies on cloned cardiac and b-cell KATP channels. Diabetes. 1998;47:1412–1418
  9. Jennings PE, Belch JJF. Free radical scavenging activity of sulfonylureas: A clinical assessment of the effect of gliclazide. Metabolism. 2000;49:23–26
  10. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:9383–9387
  11. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. Journal of Diabetes and its Complications. 2000;14:201–206
  12. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J, et al. Urinary 8-iso-prostaglandin F2α as a risk marker in patients with coronary heart disease. A matched case-control study. Circulation. 2004;109:843–848
  13. Scott NA, Jennings PE, Brown J, Belch JJF. Gliclazide: A general free radical scavenger. European Journal of Pharmacology. 1991;208:175–177
  14. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. Journal of Clinical Endocrinology and Metabolism. 2003;88:3236–3240
  15. Shimabukuro M, Higa N, Takasu N, Tagawa T, Ueda S. A single dose of nateglinide improves postchallenge endothelial dysfunction in type 2 diabetic patients. Diabetic Medicine. 2004;21:983–986
  16. Shimabukuro M, Nagamine F, Murakami K, Oshiro K, Mimura G. Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. General Pharmacology. 1994;25:697–704
  17. Shinzato T, Shimabukuro M, Higa S, Nagamine F, Murakami K, Takasu N. Effect of gliclazide on the functional response to calcium in diabetic rat heart. General Pharmacology. 1996;27:471–475
  18. Skrha J, Hodinar A, Kvasnicka J, Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabetic Medicine. 1996;13:800–805
  19. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical Biology & Medicine. 1994;16:383–391
  20. Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patorono C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. Journal of Pharmacology and Experimental Therapeutics. 1995;275:94–100
  21. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology. 1996;27:567–574

PII: S1056-8727(05)00081-4

doi: 10.1016/j.jdiacomp.2005.06.012

Journal of Diabetes and Its Complications
Volume 20, Issue 3 , Pages 179-183 , May 2006

Article Tools